Journal Home > Online First
Nano Biomedicine and Engineering https://doi.org/10.26599/NBE.2024.9290073
Review | Open Access | Online first | Published: 02 April 2024

Magnetic Resonance Imaging and Its Molecular Probes in Evaluating the Response to Tumor Treatment

Show Author's Information Dinghua Liu,  Weitao Yang,  Bingbo Zhang( )
Department of Radiology, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200065, China
Keywords:
magnetic resonance imaging (MRI), tumor treatment, molecular probes, efficacy assessment
Cite this article:
Liu D, Yang W, Zhang B. Magnetic Resonance Imaging and Its Molecular Probes in Evaluating the Response to Tumor Treatment. Nano Biomedicine and Engineering, 2024, https://doi.org/10.26599/NBE.2024.9290073
Download citation
EndNote(RIS)
BibTeX

182

Views

20

Downloads

Citations

0

Crossref

N/A

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Morphological imaging techniques are very limited in their ability to evaluate the early efficacy of tumor therapies, with the limitation of being more reflective and lagging. Many of the newer therapies are cytostatic, and tumor necrosis or lack of tumor progression is associated with a good response to treatment even in the absence of tumor shrinkage; therefore, there is an increasing need to develop techniques for the assessment of tumor efficacy. Magnetic resonance imaging (MRI), with the help of a variety of contrast mechanisms and probes, provides excellent soft-tissue imaging, high-quality anatomical signals as well as reflecting certain functional states of the tumor and molecular biological information. It can be used to differentiate between cancer and normal tissue, to noninvasively monitor tumor growth, and to identify changes in the tumor and its microenvironment in response to treatment. This review will discuss the role of magnetic resonance imaging in the assessment of tumor efficacy, with a focus on presenting research advances in magnetic resonance molecular imaging and its probes in the assessment of tumor efficacy.


menu
Abstract
Full text
Outline
About this article

Magnetic Resonance Imaging and Its Molecular Probes in Evaluating the Response to Tumor Treatment

Show Author's information Dinghua Liu, Weitao Yang, Bingbo Zhang( )
Department of Radiology, Tongji Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200065, China

Abstract

Morphological imaging techniques are very limited in their ability to evaluate the early efficacy of tumor therapies, with the limitation of being more reflective and lagging. Many of the newer therapies are cytostatic, and tumor necrosis or lack of tumor progression is associated with a good response to treatment even in the absence of tumor shrinkage; therefore, there is an increasing need to develop techniques for the assessment of tumor efficacy. Magnetic resonance imaging (MRI), with the help of a variety of contrast mechanisms and probes, provides excellent soft-tissue imaging, high-quality anatomical signals as well as reflecting certain functional states of the tumor and molecular biological information. It can be used to differentiate between cancer and normal tissue, to noninvasively monitor tumor growth, and to identify changes in the tumor and its microenvironment in response to treatment. This review will discuss the role of magnetic resonance imaging in the assessment of tumor efficacy, with a focus on presenting research advances in magnetic resonance molecular imaging and its probes in the assessment of tumor efficacy.

Keywords: magnetic resonance imaging (MRI), tumor treatment, molecular probes, efficacy assessment

References(147)

[1]

R.L. Siegel, K.D. Miller, H.E. Fuchs, et al. Cancer statistics, 2022. CA:A Cancer Journal for Clinicians, 2022, 72(1): 7−33. https://doi.org/10.3322/caac.21708
DOI Google Scholar
[2]

R.L. Wahl, H. Jacene, Y. Kasamon, et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. Journal of Nuclear Medicine, 2009, 50(Suppl 1): 122S−150S. https://doi.org/10.2967/jnumed.108.057307
DOI Google Scholar
[3]

M.K. Palmer. WHO handbook for reporting results of cancer treatment. British Journal of Cancer, 1982, 45(3): 484−485. https://doi.org/10.1038/bjc.1982.83
DOI Google Scholar
[4]

P. Therasse, S.G. Arbuck, E.A. Eisenhauer, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI:Journal of the National Cancer Institute, 2000, 92(3): 205−216. https://doi.org/10.1093/jnci/92.3.205
DOI Google Scholar
[5]

E.A. Eisenhauer, P. Therasse, J. Bogaerts, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 2009, 45(2): 228−247. https://doi.org/10.1016/j.ejca.2008.10.026
DOI Google Scholar
[6]

C.C. Ko, L.R. Yeh, Y.T. Kuo, et al. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomarker Research, 2021, 9(1): 52. https://doi.org/10.1186/s40364-021-00306-8
DOI Google Scholar
[7]

S. Saini. Radiologic measurement of tumor size in clinical trials. American Journal of Roentgenology, 2001, 176(2): 333−334. https://doi.org/10.2214/ajr.176.2.1760333
DOI Google Scholar
[8]

M.J. Ratain, S.G. Eckhardt. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. Journal of Clinical Oncology, 2004, 22(22): 4442−4445. https://doi.org/10.1200/jco.2004.07.960
DOI Google Scholar
[9]

T.C. Kwee, T. Takahara, D.W.J. Klomp, et al. Cancer imaging: Novel concepts in clinical magnetic resonance imaging. Journal of Internal Medicine, 2010, 268(2): 120−132. https://doi.org/10.1111/j.1365-2796.2010.02243.x
DOI Google Scholar
[10]

D.E. Lee, H. Koo, I.C. Sun, et al. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chemical Society Reviews, 2012, 41(7): 2656−2672. https://doi.org/10.1039/c2cs15261d
DOI Google Scholar
[11]

S.J. Gwyther, L.H. Schwartz. How to assess anti-tumour efficacy by imaging techniques. European Journal of Cancer, 2008, 44(1): 39−45. https://doi.org/10.1016/j.ejca.2007.10.010
DOI Google Scholar
[12]

B.D. Chen, L.H. Liu, R.Y. Yue, et al. Stimuli-responsive switchable MRI nanoprobe for tumor theranostics. Nano Today, 2023, 51: 101931. https://doi.org/10.1016/j.nantod.2023.101931
DOI Google Scholar
[13]

E. Terreno, D.D. Castelli, A. Viale, et al. Challenges for molecular magnetic resonance imaging. Chemical Reviews, 2010, 110(5): 3019−3042. https://doi.org/10.1021/cr100025t
DOI Google Scholar
[14]
J. Wahsner, , Gale, E. M., Rodríguez-Rodríguez, A., Caravan, P. Chemistry of MRI contrast agents: Current challenges and new frontiers. Chemical Reviews, 2019, 119(2): 957–1057.
DOI
[15]

X. Jin, W.T. Yang, Y. Xu, wt al. Emerging strategies of activatable MR imaging probes and their advantages for biomedical applications. VIEW, 2021, 2(5): 20200141. https://doi.org/10.1002/viw.20200141
DOI Google Scholar
[16]

R. Glynne-Jones, L. Wyrwicz, E. Tiret, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28: iv22−iv40. https://doi.org/10.1093/annonc/mdx224
DOI Google Scholar
[17]

T. Anani, S. Rahmati, N. Sultana, et al. MRI-traceable theranostic nanoparticles for targeted cancer treatment. Theranostics, 2021, 11(2): 579−601. https://doi.org/10.7150/thno.48811
DOI Google Scholar
[18]

D. Leung, X. Han, T. Mikkelsen, et al. Role of MRI in primary brain tumor evaluation. Journal of National Comprehensive Cancer Network, 2014, 12(11): 1561−1568. https://doi.org/10.6004/jnccn.2014.0156
DOI Google Scholar
[19]

B.B. Kasten, N. Udayakumar, J.W. Leavenworth, et al. Current and future imaging methods for evaluating response to immunotherapy in neuro-oncology. Theranostics, 2019, 9(17): 5085−5104. https://doi.org/10.7150/thno.34415
DOI Google Scholar
[20]

D.A. Torigian, S.S. Huang, M. Houseni, et al. Functional imaging of cancer with emphasis on molecular techniques. CA:A Cancer Journal for Clinicians, 2007, 57(4): 206−224. https://doi.org/10.3322/canjclin.57.4.206
DOI Google Scholar
[21]
A. Dzik-Jurasz, C. Domenig, M. George, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. The Lancet, 2002, 360(9329): 307–308.
DOI
[22]

L. Kwock, J.K. Smith, M. Castillo, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: Brain, breast, and prostate cancer. The Lancet Oncology, 2006, 7(10): 859−868. https://doi.org/10.1016/s1470-2045(06)70905-6
DOI Google Scholar
[23]

A.R. Padhani, C. Hayes, L. Assersohn, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results. Radiology, 2006, 239(2): 361−374. https://doi.org/10.1148/radiol.2392021099
DOI Google Scholar
[24]

J.Y. Liang, Q.Q. Cheng, J.X. Huang, et al. Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI. Angiogenesis, 2019, 22(3): 457−470. https://doi.org/10.1007/s10456-019-09670-4
DOI Google Scholar
[25]

F. Giganti, A. Ambrosi, D. Chiari, et al. Apparent diffusion coefficient by diffusion-weighted magnetic resonance imaging as a sole biomarker for staging and prognosis of gastric cancer. Chinese Journal of Cancer Research, 2017, 29(2): 118−126. https://doi.org/10.21147/j.issn.1000-9604.2017.02.04
DOI Google Scholar
[26]
T.L. Chenevert, C.R. Meyer, B.A. Moffat, et al. Diffusion MRI: A new strategy for assessment of cancer therapeutic efficacy. Molecular Imaging, 2002, 1(4).
DOI
[27]

R.L. McLaughlin, D.C. Newitt, L.J. Wilmes, et al. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: A pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. Journal of Magnetic Resonance Imaging, 2014, 39(5): 1308−1313. https://doi.org/10.1002/jmri.24283
DOI Google Scholar
[28]

X.D. Shi, W.T. Yang, Q. Ma, et al. Hemoglobin-mediated biomimetic synthesis of paramagnetic O2-evolving theranostic nanoprobes for MR imaging-guided enhanced photodynamic therapy of tumor. Theranostics, 2020, 10(25): 11607−11621. https://doi.org/10.7150/thno.46228
DOI Google Scholar
[29]

P. Jagoda, J. Fleckenstein, M. Sonnhoff, et al. Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC. Cancer Imaging, 2021, 21(1): 15. https://doi.org/10.1186/s40644-021-00384-9
DOI Google Scholar
[30]

V. Zampa, G. Aringhieri, R. Tintori, et al. The added value of the visual analysis of DWI in post-surgery follow-up of soft tissue sarcoma of the extremities: Do we really need ADC. La Radiologia Medica, 2023, 128(4): 467−479. https://doi.org/10.1007/s11547-023-01613-w
DOI Google Scholar
[31]

P. Ditter, E. Hattingen. MR-spectroscopy in brain tumors. Radiologe, 2017, 57(6): 450−458. https://doi.org/10.1007/s00117-017-0241-z
DOI Google Scholar
[32]

J.R. Roebuck, K.M. Cecil, M.D. Schnall, et al. Human breast lesions: Characterization with proton MR spectroscopy. Radiology, 1998, 209(1): 269−275. https://doi.org/10.1148/radiology.209.1.9769842
DOI Google Scholar
[33]

K.M. Cecil. Proton magnetic resonance spectroscopy technique for the neuroradiologist. Neuroimaging Clinics of North America, 2013, 23(3): 381−392. https://doi.org/10.1016/j.nic.2012.10.003
DOI Google Scholar
[34]
M.F. Kircher, J.R. Allport, E.E. Graves, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Research, 2003, 63(20): 6838–6846.
[35]

A. Saha, K.K. Peck, E. Lis, et al. Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases. Spine, 2014, 39(24): E1433−E1440. https://doi.org/10.1097/brs.0000000000000570
DOI Google Scholar
[36]

T. Christen, B. Lemasson, N. Pannetier, et al. Is T2* enough to assess oxygenation? quantitative blood oxygen level–dependent analysis in brain tumor. Radiology, 2012, 262(2): 495−502. https://doi.org/10.1148/radiol.11110518
DOI Google Scholar
[37]

J.B. Cao, H.Q. An, X.L. Huang, et al. Monitoring of the tumor response to nano-graphene oxide-mediated photothermal/photodynamic therapy by diffusion-weighted and BOLD MRI. Nanoscale, 2016, 8(19): 10152−10159. https://doi.org/10.1039/c6nr02012g
DOI Google Scholar
[38]

S. Gross, A. Gilead, A. Scherz, et al. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nature Medicine, 2003, 9(10): 1327−1331. https://doi.org/10.1038/nm940
DOI Google Scholar
[39]

A.A. Gilad, T. Israely, H. Dafni. et al. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: The role of stroma cells in tumor angiogenesis. International Journal of Cancer, 2005, 117(2): 202−211. https://doi.org/10.1002/ijc.21179
DOI Google Scholar
[40]

S.P. Rowe, M.G. Pomper. Molecular imaging in oncology: Current impact and future directions. CA:A Cancer Journal for Clinicians, 2022, 72(4): 333−352. https://doi.org/10.3322/caac.21713
DOI Google Scholar
[41]

R. Weissleder, M.J. Pittet. Imaging in the era of molecular oncology. Nature, 2008, 452(7187): 580−589. https://doi.org/10.1038/nature06917
DOI Google Scholar
[42]

R. Weissleder. Molecular imaging in cancer. Science, 2006, 312(5777): 1168−1171. https://doi.org/10.1126/science.1125949
DOI Google Scholar
[43]

W. Reichardt, D. von Elverfeldt. Preclinical applications of magnetic resonance imaging in oncology. Recent Results in Cancer Research Fortschritte Der Krebsforschung Progres Dans Les Recherches Sur Le Cancer, 2020, 216: 405−437. https://doi.org/10.1007/978-3-030-42618-7_12
DOI Google Scholar
[44]

Z.R. Lu, V. Laney, Y.J. Li. Targeted contrast agents for magnetic resonance molecular imaging of cancer. Accounts of Chemical Research, 2022, 55(19): 2833−2847. https://doi.org/10.1021/acs.accounts.2c00346
DOI Google Scholar
[45]

B.A. Carneiro, W.S. El-Deiry. Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology, 2020, 17(7): 395−417. https://doi.org/10.1038/s41571-020-0341-y
DOI Google Scholar
[46]

A. Najafov, H.B. Chen, J.Y. Yuan. Necroptosis and cancer. Trends in Cancer, 2017, 3(4): 294−301. https://doi.org/10.1016/j.trecan.2017.03.002
DOI Google Scholar
[47]

Y.P. Wang, W.Q. Gao, X.Y. Shi, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature, 2017, 547(7661): 99−103. https://doi.org/10.1038/nature22393
DOI Google Scholar
[48]

J. Debnath, N. Gammoh, K.M. Ryan. Autophagy and autophagy-related pathways in cancer. Nature Reviews Molecular Cell Biology, 2023, 24(8): 560−575. https://doi.org/10.1038/s41580-023-00585-z
DOI Google Scholar
[49]

J.P. Friedmann Angeli, D.V. Krysko, M. Conrad. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nature Reviews Cancer, 2019, 19(7): 405−414. https://doi.org/10.1038/s41568-019-0149-1
DOI Google Scholar
[50]

P. Tsvetkov, S. Coy, B. Petrova, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254−1261. https://doi.org/10.1126/science.abf0529
DOI Google Scholar
[51]

G. Pistritto, D. Trisciuoglio, C. Ceci, et al. Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging, 2016, 8(4): 603−619. https://doi.org/10.18632/aging.100934
DOI Google Scholar
[52]

S. Fulda, K.M. Debatin. Targeting apoptosis pathways in cancer therapy. Current Cancer Drug Targets, 2004, 4(7): 569−576. https://doi.org/10.2174/1568009043332763
DOI Google Scholar
[53]

V.A. Fadok, D.L. Bratton, D.M. Rose, et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature, 2000, 405(6782): 85−90. https://doi.org/10.1038/35011084
DOI Google Scholar
[54]
G. Odabaei, D. Chatterjee, A.R. Jazirehi, et al. Raf-1 kinase inhibitor protein: Structure, function, regulation of cell signaling, and pivotal role in apoptosis. In: Advances in Cancer Research. Amsterdam: Elsevier, 2004: 169–200. https://doi.org/10.1016/s0065-230x(04)91005-6
DOI
[55]

A.A. Rybczynska, H.H. Boersma, S. de Jong, et al. Avenues to molecular imaging of dying cells: Focus on cancer. Medicinal Research Reviews, 2018, 38(6): 1713−1768. https://doi.org/10.1002/med.21495
DOI Google Scholar
[56]

D.J. Zhang, Q.M. Jin, C.H. Jiang, et al. Imaging cell death: Focus on early evaluation of tumor response to therapy. Bioconjugate Chemistry, 2020, 31(4): 1025−1051. https://doi.org/10.1021/acs.bioconjchem.0c00119
DOI Google Scholar
[57]

H.L. Xu, K.L. Mao, Y.P. Huang, et al. Glioma-targeted superparamagnetic iron oxide nanoparticles as drug-carrying vehicles for theranostic effects. Nanoscale, 2016, 8(29): 14222−14236. https://doi.org/10.1039/c6nr02448c
DOI Google Scholar
[58]

S. Shalini, L. Dorstyn, S. Dawar, et al. Old, new and emerging functions of caspases. Cell Death &Differentiation, 2015, 22(4): 526−539. https://doi.org/10.1038/cdd.2014.216
DOI Google Scholar
[59]

B. Yoo, M.D. Pagel. A PARACEST MRI contrast agent to detect enzyme activity. Journal of the American Chemical Society, 2006, 128(43): 14032−14033. https://doi.org/10.1021/ja063874f
DOI Google Scholar
[60]

D.J. Ye, A.J. Shuhendler, P. Pandit, et al. Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis. Chemical Science, 2014, 5(10): 3845−3852. https://doi.org/10.1039/c4sc01392a
DOI Google Scholar
[61]

Y. Yuan, Z.L. Ding, J.C. Qian, et al. Casp3/7-instructed intracellular aggregation of Fe3O4 nanoparticles enhances T2 MR imaging of tumor apoptosis. Nano Letters, 2016, 16(4): 2686−2691. https://doi.org/10.1021/acs.nanolett.6b00331
DOI Google Scholar
[62]

H. Li, G. Parigi, C. Luchinat, et al. Bimodal fluorescence-magnetic resonance contrast agent for apoptosis imaging. Journal of the American Chemical Society, 2019, 141(15): 6224−6233. https://doi.org/10.1021/jacs.8b13376
DOI Google Scholar
[63]

H. Pelicano, D. Carney, P. Huang. ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates, 2004, 7(2): 97−110. https://doi.org/10.1016/j.drup.2004.01.004
DOI Google Scholar
[64]

C. Gorrini, I.S. Harris, T.W. Mak. Modulation of oxidative stress as an anticancer strategy. Nature Reviews Drug Discovery, 2013, 12(12): 931−947. https://doi.org/10.1038/nrd4002
DOI Google Scholar
[65]

B.L. Dai, R. Zhang, S.H. Qi, et al. Intravital molecular imaging reveals that ROS-caspase-3-GSDME-induced cell punching enhances humoral immunotherapy targeting intracellular tumor antigens. Theranostics, 2022, 12(17): 7603−7623. https://doi.org/10.7150/thno.75966
DOI Google Scholar
[66]
G. Bačić, A. Pavićević, F. Peyrot. In vivo evaluation of different alterations of redox status by studying pharmacokinetics of nitroxides using magnetic resonance techniques. Redox Biology, 2016, 8: 226–242. https://doi.org/10.1016/j.redox.2015.10.007
DOI
[67]

H. Wang, D.Q. Yu, B. Li, et al. Ultrasensitive magnetic resonance imaging of systemic reactive oxygen species in vivo for early diagnosis of sepsis using activatable nanoprobes. Chemical Science, 2019, 10(13): 3770−3778. https://doi.org/10.1039/c8sc04961k
DOI Google Scholar
[68]
X.L.Li, Y. Liu, X.W. Qi, et al. Sensitive activatable nanoprobes for real-time ratiometric magnetic resonance imaging of reactive oxygen species and ameliorating inflammation in vivo. Advanced Materials, 2022, 34(19): 2109004.
DOI
[69]

Z.J. Zhou, H.Z. Deng, W.J. Yang, et al. Early stratification of radiotherapy response by activatable inflammation magnetic resonance imaging. Nature Communications, 2020, 11: 3032. https://doi.org/10.1038/s41467-020-16771-y
DOI Google Scholar
[70]
K. Deng, B. Wu, C.X. Wang, et al. An oxidation-enhanced magnetic resonance imaging probe for visual and specific detection of singlet oxygen generated in photodynamic cancer therapy in vivo. Advanced Healthcare Materials, 2020, 9(16): 2000533.
DOI
[71]

D. Trachootham, J. Alexandre, P. Huang. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach. Nature Reviews Drug Discovery, 2009, 8(7): 579−591. https://doi.org/10.1038/nrd2803
DOI Google Scholar
[72]

S. Dixon, K. Lemberg, M. Lamprecht, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5): 1060−1072. https://doi.org/10.1016/j.cell.2012.03.042
DOI Google Scholar
[73]

S.J. Dixon, B.R. Stockwell. The role of iron and reactive oxygen species in cell death. Nature Chemical Biology, 2014, 10(1): 9−17. https://doi.org/10.1038/nchembio.1416
DOI Google Scholar
[74]

X. Chen, R. Kang, G. Kroemer, et al. Broadening horizons: The role of ferroptosis in cancer. Nature Reviews Clinical Oncology, 2021, 18(5): 280−296. https://doi.org/10.1038/s41571-020-00462-0
DOI Google Scholar
[75]

G. Lei, L. Zhuang, B.Y. Gan. Targeting ferroptosis as a vulnerability in cancer. Nature Reviews Cancer, 2022, 22(7): 381−396. https://doi.org/10.1038/s41568-022-00459-0
DOI Google Scholar
[76]

G.Q. Guan, C. Zhang, H.Y. Liu, et al. Ternary alloy PtWMn as a Mn nanoreservoir for high-field MRI monitoring and highly selective ferroptosis therapy. Angewandte Chemie International Edition, 2022, 61(31): 2117229. https://doi.org/10.1002/anie.202117229
DOI Google Scholar
[77]

I. Martínez-Reyes, N.S. Chandel. Cancer metabolism: Looking forward. Nature Reviews Cancer, 2021, 21(10): 669−680. https://doi.org/10.1038/s41568-021-00378-6
DOI Google Scholar
[78]

M.G. Vander Heiden, L.C. Cantley, C.B. Thompson. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 2009, 324(5930): 1029−1033. https://doi.org/10.1126/science.1160809
DOI Google Scholar
[79]

R.A. Cairns, I.S. Harris, T.W. Mak. Regulation of cancer cell metabolism. Nature Reviews Cancer, 2011, 11(2): 85−95. https://doi.org/10.1038/nrc2981
DOI Google Scholar
[80]

K. Hönigova, J. Navratil, B. Peltanova, et al. Metabolic tricks of cancer cells. Biochimica et Biophysica - Acta Reviews on Cancer, 2022, 1877(3): 188705. https://doi.org/10.1016/j.bbcan.2022.188705
DOI Google Scholar
[81]

O. Jacobson, X.Y. Chen. Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. theranostic approaches to improve therapeutics. Pharmacological Reviews, 2013, 65(4): 1214−1256. https://doi.org/10.1124/pr.113.007625
DOI Google Scholar
[82]

M.G. Vander Heiden, R.J. DeBerardinis. Understanding the intersections between metabolism and cancer biology. Cell, 2017, 168(4): 657−669. https://doi.org/10.1016/j.cell.2016.12.039
DOI Google Scholar
[83]

A.A. Neves, Y.A. Wainman, A. Wright, et al. Imaging glycosylation in vivo by metabolic labeling and magnetic resonance imaging. Angewandte Chemie International Edition, 2016, 55(4): 1286−1290. https://doi.org/10.1002/anie.201509858
DOI Google Scholar
[84]

Y. Yuan, J. Zhang, X.L. Qi, et al. Furin-mediated intracellular self-assembly of olsalazine nanoparticles for enhanced magnetic resonance imaging and tumour therapy. Nature Materials, 2019, 18(12): 1376−1383. https://doi.org/10.1038/s41563-019-0503-4
DOI Google Scholar
[85]
Y. Kondo, H. Nonaka, Y. Takakusagi, et al. Design of nuclear magnetic resonance molecular probes for hyperpolarized bioimaging. Angewandte Chemie International Edition, 2021, 60(27): 14779–14799.
DOI
[86]

S. Siddiqui, S. Kadlecek, M. Pourfathi, et al. The use of hyperpolarized carbon-13 magnetic resonance for molecular imaging. Advanced Drug Delivery Reviews, 2017, 113: 3−23. https://doi.org/10.1016/j.addr.2016.08.011
DOI Google Scholar
[87]

S.E. Day, M.I. Kettunen, F.A. Gallagher, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nature Medicine, 2007, 13(11): 1382−1387. https://doi.org/10.1038/nm1650
DOI Google Scholar
[88]

N. Koyasu, F. Hyodo, R. Iwasaki, et al. Spatiotemporal imaging of redox status using in vivo dynamic nuclear polarization magnetic resonance imaging system for early monitoring of response to radiation treatment of tumor. Free Radical Biology and Medicine, 2022, 179: 170−180. https://doi.org/10.1016/j.freeradbiomed.2021.12.311
DOI Google Scholar
[89]

P. Carmeliet, R.K. Jain. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801): 249−257. https://doi.org/10.1038/35025220
DOI Google Scholar
[90]

R.A. Sharma, A.L. Harris, A.G. Dalgleish, et al. Angiogenesis as a biomarker and target in cancer chemoprevention. The Lancet Oncology, 2001, 2(12): 726−732. https://doi.org/10.1016/s1470-2045(01)00586-1
DOI Google Scholar
[91]

P. Carmeliet, R.K. Jain. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473(7347): 298−307. https://doi.org/10.1038/nature10144
DOI Google Scholar
[92]

A.R. Hsu, X.Y. Chen. Advances in anatomic, functional, and molecular imaging of angiogenesis. Journal of Nuclear Medicine, 2008, 49(4): 511−514. https://doi.org/10.2967/jnumed.107.050179
DOI Google Scholar
[93]

Z.Y. Jia, L.N. Song, F.C. Zang, et al. Active-target T1-weighted MR imaging of tiny hepatic tumor via RGD modified ultra-small Fe3O4 nanoprobes. Theranostics, 2016, 6(11): 1780−1791. https://doi.org/10.7150/thno.14280
DOI Google Scholar
[94]

A.K. Olsson, A. Dimberg, J. Kreuger, et al. VEGF receptor signalling? in control of vascular function. Nature Reviews Molecular Cell Biology, 2006, 7(5): 359−371. https://doi.org/10.1038/nrm1911
DOI Google Scholar
[95]

M.V. Backer, Z. Levashova, V. Patel, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nature Medicine, 2007, 13(4): 504−509. https://doi.org/10.1038/nm1522
DOI Google Scholar
[96]

F., Zhang, X.L. Huang, L. Zhu, et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials, 2012, 33(21): 5414−5422. https://doi.org/10.1016/j.biomaterials.2012.04.032
DOI Google Scholar
[97]

D.B. Ellegala, H. Leong-Poi, J.E. Carpenter, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation, 2003, 108(3): 336−341. https://doi.org/10.1161/01.CIR.0000080326.15367.0C
DOI Google Scholar
[98]

D.A. Sipkins, D.A. Cheresh, M.R. Kazemi, et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nature Medicine, 1998, 4(5): 623−626. https://doi.org/10.1038/nm0598-623
DOI Google Scholar
[99]

G. Suna, W. Wojakowski, M. Lynch, et al. Extracellular matrix proteomics reveals interplay of aggrecan and aggrecanases in vascular remodeling of stented coronary arteries. Circulation, 2018, 137(2): 166−183. https://doi.org/10.1161/circulationaha.116.023381
DOI Google Scholar
[100]

J.O. Kaufmann, J. Brangsch, A. Kader, et al. ADAMTS4-specific MR probe to assess aortic aneurysms in vivo using synthetic peptide libraries. Nature Communications, 2022, 13: 2867. https://doi.org/10.1038/s41467-022-30464-8
DOI Google Scholar
[101]
A.Y. Louie, M.M. Hüber, E.T. Ahrens, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnology, 2000, 18(3): 321–325.
DOI
[102]

J.H. Kang, J.K. Chung. Molecular-genetic imaging based on reporter gene expression. Journal of Nuclear Medicine, 2008, 49(Suppl 2): 164S−179S. https://doi.org/10.2967/jnumed.107.045955
DOI Google Scholar
[103]

A.A. Gilad, K. Ziv, M.T. McMahon, et al. MRI reporter genes. Jounral of Nuclear Medicine, 2008, 49(12): 1905−1908. https://doi.org/10.2967/jnumed.108.053520
DOI Google Scholar
[104]
Arena, F., Singh, J. B., Gianolio, E., Stefanìa, R., Aime, S. β-gal gene expression MRI reporter in melanoma tumor cells. design, synthesis, and in vitro and in vivo testing of a Gd(III) containing probe forming a high relaxivity, melanin-like structure upon β-gal enzymatic activation. Bioconjugate Chemistry, 2011, 22(12): 2625–2635.
DOI
[105]
M.H. Cao, J.J. Mao, X.H. Duan, et al. In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging. International Journal of Cancer, 2018, 142(5): 1033–1046.
DOI
[106]

L.B. Kennedy, A.K.S. Salama. A review of cancer immunotherapy toxicity. CA:A Cancer Journal for Clinicians, 2020, 70(2): 86−104. https://doi.org/10.3322/caac.21596
DOI Google Scholar
[107]
W.J. Lesterhuis, A. Bosco, M.J. Millward, et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: Unravelling complexity. Nature Reviews Drug Discovery, 2017, 16(4): 264–272.
DOI
[108]

Z.B. Xiao, E. Puré. Imaging of T-cell responses in the context of cancer immunotherapy. Cancer Immunology Research, 2021, 9(5): 490−502. https://doi.org/10.1158/2326-6066.cir-20-0678
DOI Google Scholar
[109]

A.J. Grippin, B. Wummer, T. Wildes, et al. Dendritic cell-activating magnetic nanoparticles enable early prediction of antitumor response with magnetic resonance imaging. ACS Nano, 2019, 13(12): 13884−13898. https://doi.org/10.1021/acsnano.9b05037
DOI Google Scholar
[110]

I. Melero, E. Castanon, M. Alvarez, et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology, 2021, 18(9): 558−576. https://doi.org/10.1038/s41571-021-00507-y
DOI Google Scholar
[111]

J. Levi, T. Lam, S.R. Goth, et al. Imaging of activated T cells as an early predictor of immune response to anti-PD-1 therapy. Cancer Research, 2019, 79(13): 3455−3465. https://doi.org/10.1158/0008-5472.can-19-0267
DOI Google Scholar
[112]

C.R. Shi, Q.Y. Zhang, Y.Y. Yao, et al. Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics. Nature Nanotechnology, 2023, 18(1): 86−97. https://doi.org/10.1038/s41565-022-01261-7
DOI Google Scholar
[113]

M. Hockel, P. Vaupel. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. JNCI Journal of the National Cancer Institute, 2001, 93(4): 266−276. https://doi.org/10.1093/jnci/93.4.266
DOI Google Scholar
[114]

M. Pastorek, V. Simko, M. Takacova, et al. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy. International Journal of Oncology, 2015, 47(1): 51−60. https://doi.org/10.3892/ijo.2015.2987
DOI Google Scholar
[115]

P. Vaupel, A. Mayer. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer and Metastasis Reviews, 2007, 26(2): 225−239. https://doi.org/10.1007/s10555-007-9055-1
DOI Google Scholar
[116]

W.R. Wilson, M.P. Hay. Targeting hypoxia in cancer therapy. Nature Reviews Cancer, 2011, 11(6): 393−410. https://doi.org/10.1038/nrc3064
DOI Google Scholar
[117]

S.K. Chitneni, G.M. Palmer, M.R. Zalutsky, et al. Molecular imaging of hypoxia. Journal of Nuclear Medicine, 2011, 52(2): 165−168. https://doi.org/10.2967/jnumed.110.075663
DOI Google Scholar
[118]

J.N. Liu, W.B. Bu, J.L. Shi. Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia. Chemical Reviews, 2017, 117(9): 6160−6224. https://doi.org/10.1021/acs.chemrev.6b00525
DOI Google Scholar
[119]

J. Liu, H. Cabral, B. Song, et al. Nanoprobe-based magnetic resonance imaging of hypoxia predicts responses to radiotherapy, immunotherapy, and sensitizing treatments in pancreatic tumors. ACS Nano, 2021, 15(8): 13526−13538. https://doi.org/10.1021/acsnano.1c04263
DOI Google Scholar
[120]

V. Estrella, T.A. Chen, M. Lloyd, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Research, 2013, 73(5): 1524−1535. https://doi.org/10.1158/0008-5472.can-12-2796
DOI Google Scholar
[121]

B.A. Webb, M. Chimenti, M.P. Jacobson, et al. Dysregulated pH: A perfect storm for cancer progression. Nature Reviews Cancer, 2011, 11(9): 671−677. https://doi.org/10.1038/nrc3110
DOI Google Scholar
[122]

X.M. Zhang, Y.X. Lin, R.J. Gillies. Tumor pH and its measurement. Journal of Nuclear Medicine, 2010, 51(8): 1167−1170. https://doi.org/10.2967/jnumed.109.068981
DOI Google Scholar
[123]

P. Mi, D. Kokuryo, H. Cabral, et al. A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nature Nanotechnology, 2016, 11(8): 724−730. https://doi.org/10.1038/nnano.2016.72
DOI Google Scholar
[124]

X.L. Zhu, X.X. Tang, H.Y. Lin, et al. A fluorinated ionic liquid-based activatable 19F MRI platform detects biological targets. Chem, 2020, 6(5): 1134−1148. https://doi.org/10.1016/j.chempr.2020.01.023
DOI Google Scholar
[125]

H. Sato, T. Takino, Y. Okada, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 1994, 370(6484): 61−65. https://doi.org/10.1038/370061a0
DOI Google Scholar
[126]
J. Chang, W.Q. Cai, C.J. Liang, et al. Enzyme-instructed activation of pro-protein therapeutics in vivo. Journal of the American Chemical Society, 2019, 141(45): 18136–18141.
DOI
[127]

M. Egeblad, Z. Werb. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2002, 2(3): 161−174. https://doi.org/10.1038/nrc745
DOI Google Scholar
[128]

J.S. Rao. Molecular mechanisms of glioma invasiveness: The role of proteases. Nature Reviews Cancer, 2003, 3(7): 489−501. https://doi.org/10.1038/nrc1121
DOI Google Scholar
[129]

K. Kessenbrock, V. Plaks, Z. Werb. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 2010, 141(1): 52−67. https://doi.org/10.1016/j.cell.2010.03.015
DOI Google Scholar
[130]

R. Roy, J. Yang, M.A. Moses. Matrix metalloproteinases As novel biomarker s and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 2009, 27(31): 5287−5297. https://doi.org/10.1200/jco.2009.23.5556
DOI Google Scholar
[131]
V. Amirbekian, J.G.S. Aguinaldo, S. Amirbekian, et al. Atherosclerosis and matrix metalloproteinases: Experimental molecular MR imaging in vivo. Radiology, 2009, 251(2): 429–438.
DOI
[132]

E.S. Olson, T. Jiang, T.A. Aguilera, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(9): 4311−4316. https://doi.org/10.1073/pnas.0910283107
DOI Google Scholar
[133]

H. Shi, Y. Sun, R. Yan, et al. Magnetic semiconductor Gd-doping CuS nanoparticles as activatable nanoprobes for bimodal imaging and targeted photothermal therapy of gastric tumors. Nano Letters, 2019, 19(2): 937−947. https://doi.org/10.1021/acs.nanolett.8b04179
DOI Google Scholar
[134]

L. Guzman-Rojas, R. Rangel, A. Salameh, et al. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(5): 1637−1642. https://doi.org/10.1073/pnas.1120790109
DOI Google Scholar
[135]

R. Hata, H. Nonaka, Y. Takakusagi, et al. Design of a hyperpolarized molecular probe for detection of aminopeptidase N activity. Angewandte Chemie International Edition, 2016, 55(5): 1765−1768. https://doi.org/10.1002/anie.201509457
DOI Google Scholar
[136]
Y. Saito, H. Yatabe, I. Tamura, et al. Structure-guided design enables development of a hyperpolarized molecular probe for the detection of aminopeptidase N activity in vivo. Science Advances, 2022, 8(13): eabj2667.
DOI
[137]

M.F. Kircher, J.K. Willmann. Molecular body imaging: MR imaging, CT, and US. part I. principles. Radiology, 2012, 263(3): 633−643. https://doi.org/10.1148/radiol.12102394
DOI Google Scholar
[138]

J.M. Winfield, G.S. Payne, N.M. DeSouza. Functional MRI and CT biomarkers in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42(4): 562−578. https://doi.org/10.1007/s00259-014-2979-0
DOI Google Scholar
[139]

J.J. Platt, M.L. Ramanathan, R.A. Crosbie, et al. C-reactive protein as a predictor of postoperative infective complications after curative resection in patients with colorectal cancer. Annals of Surgical Oncology, 2012, 19(13): 4168−4177. https://doi.org/10.1245/s10434-012-2498-9
DOI Google Scholar
[140]

C.N. Loynachan, A.P. Soleimany, J.S. Dudani, et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nature Nanotechnology, 2019, 14(9): 883−890. https://doi.org/10.1038/s41565-019-0527-6
DOI Google Scholar
[141]

S.Q. He, J. Song, J.L. Qu, et al. Crucial breakthrough of second near-infrared biological window fluorophores: Design and synthesis toward multimodal imaging and theranostics. Chemical Society Reviews, 2018, 47(12): 4258−4278. https://doi.org/10.1039/c8cs00234g
DOI Google Scholar
[142]

J.S. Huang, L.C. Su, C. Xu, et al. Molecular radio afterglow probes for cancer radiodynamic theranostics. Nature Materials, 2023, 22(11): 1421−1429. https://doi.org/10.1038/s41563-023-01659-1
DOI Google Scholar
[143]

Y. X. Hu, J.Y. Zhang, Y.X. Miao, et al. Enzyme-mediated in situ self-assembly promotes in vivo bioorthogonal reaction for pretargeted multimodality imaging. Angewandte Chemie International Edition, 2021, 60(33): 18082−18093. https://doi.org/10.1002/anie.202103307
DOI Google Scholar
[144]

F. Seith, A. Forschner, B. Weide, et al. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer, 2020, 8(2): e000656. https://doi.org/10.1136/jitc-2020-000656corr1
DOI Google Scholar
[145]

C. Bai, Z.Y. Jia, L.N. Song, et al. Time-dependent T1–T2 switchable magnetic resonance imaging realized by c(RGDyK) modified ultrasmall Fe3O4 nanoprobes. Advanced Functional Materials, 2018, 28(32): 1802281. https://doi.org/10.1002/adfm.201802281
DOI Google Scholar
[146]

Z.Y. Shen, T.X. Chen, X.H. Ma, et al. Multifunctional theranostic nanoparticles based on exceedingly small magnetic iron oxide nanoparticles for T1-weighted magnetic resonance imaging and chemotherapy. ACS Nano, 2017, 11(11): 10992−11004. https://doi.org/10.1021/acsnano.7b04924
DOI Google Scholar
[147]

J. Wang, Y.H. Jia, Q.Y. Wang, et al. An ultrahigh-field-tailored T1–T2 dual-mode MRI contrast agent for high-performance vascular imaging. Advanced Materials, 2021, 33(2): 2004917. https://doi.org/10.1002/adma.202004917
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 10 December 2023
Revised: 01 February 2024
Accepted: 27 February 2024
Published: 02 April 2024

Copyright

© The Author(s) 2024.

Acknowledgements

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grants 82272137, 82272055), National Key Research and Development Project (Grant 2022YFB3804500), Shanghai Municipal Commission of Health and Family Planning Project (Grant 20204Y0032), Shanghai Sailing Program (Grant 21YF1436600), and the Fundamental Research Funds for the Central Universities (Grant 22120220585).

Rights and permissions

This is an open-access article distributed under  the  terms  of  the  Creative  Commons  Attribution  4.0 International  License (CC BY) (http://creativecommons.org/licenses/by/4.0/), which  permits  unrestricted  use,  distribution,  and reproduction in any medium, provided the original author and source are credited.

Return